Phenotypic profiling of CD34<sup>+</sup> cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia
Cristina Bugarin,
Laura Antolini,
Chiara Buracchi,
Sergio Matarraz,
Tiziana Angela Coliva,
Vincent H. van der Velden,
Tomasz Szczepanski,
Elaine Sobral da Costa,
Alita van der Sluijs,
Michaela Novakova,
Ester Mejstrikova,
Stefan Nierkens,
Fabiana Vieira de Mello,
Paula Fernandez,
Carmen Aanei,
Łukasz Sędek,
Luisa Strocchio,
Riccardo Masetti,
Laura Sainati,
Jan Philippé,
Maria Grazia Valsecchi,
Franco Locatelli,
Jacques J.M. van Dongen,
Andrea Biondi,
Alberto Orfao,
Giuseppe Gaipa
Affiliations
Cristina Bugarin
Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza (MB)
Laura Antolini
Center of Biostatistics for Clinical Epidemiology, Dipartimento di Medicina e Chirurgia, Università degli Studi Milano-Bicocca, Monza (MB)
Chiara Buracchi
Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza (MB)
Sergio Matarraz
Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, CIBERONC and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca
Tiziana Angela Coliva
Department of Pediatrics, Fondazione IRCCS San Gerardo dei Tintori, Monza (MB)
Vincent H. van der Velden
Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam
Tomasz Szczepanski
Department of Pediatric Hematology and Oncology, Medical University of Silesia (SUM), Zabrze
Elaine Sobral da Costa
Department of Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro
Alita van der Sluijs
Department of Immunohematology and Blood Transfusion (IHB) Leiden University Medical Center (LUMC), Leiden
Michaela Novakova
CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Ester Mejstrikova
CLIP-Department of Pediatric Hematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
Stefan Nierkens
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Fabiana Vieira de Mello
Department of Pediatrics, Federal University of Rio de Janeiro, Rio de Janeiro
Paula Fernandez
Institute for Laboratory Medicine, Kantonsspital Aarau AG, Aarau
Carmen Aanei
Hematology Laboratory CHU de Saint-Etienne, Saint-Etienne, Cedex 2
Łukasz Sędek
Department of Pediatric Hematology and Oncology, Medical University of Silesia (SUM), Zabrze
Luisa Strocchio
Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesu’, Sapienza University of Rome
Riccardo Masetti
Pediatric Oncology and Hematology Unit 'Lalla Seràgnoli', IRCCS Azienda Ospedaliero- Universitaria di Bologna, Bologna
Laura Sainati
Dipartimento di Salute della Donna e del Bambino, Clinica di Oncoematologia Pediatrica, Azienda Ospedale Università di Padova, Padua
Jan Philippé
Department of Laboratory Medicine, Ghent University Hospital, Ghent
Maria Grazia Valsecchi
Center of Biostatistics for Clinical Epidemiology, Dipartimento di Medicina e Chirurgia, Università degli Studi Milano-Bicocca, Monza (MB)
Franco Locatelli
Department of Pediatric Hematology and Oncology IRCCS Ospedale Pediatrico Bambino Gesu’, Sapienza University of Rome
Jacques J.M. van Dongen
Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, CIBERONC and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain; Department of Immunohematology and Blood Transfusion (IHB) Leiden University Medical Center (LUMC), Leiden
Andrea Biondi
Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza (MB), Italy; Dipartimento di Medicina e Chirurgia, Università degli Studi Milano-Bicocca, Monza (MB)
Alberto Orfao
Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca, CIBERONC and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca
Giuseppe Gaipa
Centro Tettamanti, Fondazione IRCCS San Gerardo dei Tintori, Monza (MB)
Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and follow-up of hematological malignancies, nevertheless it is not routinely used for JMML diagnosis. Herewith, we characterized the CD34+ hematopoietic precursor cells collected from 31 children with JMML using a combination of standardized EuroFlow antibody panels to assess the ability to discriminate JMML cells from normal/reactive bone marrow cell as controls (n=29) or from cells of children with other hematological diseases mimicking JMML (n=9). CD34+ precursors in JMML showed markedly reduced B-cell and erythroid-committed precursors compared to controls, whereas monocytic and CD7+ lymphoid precursors were significantly expanded. Moreover, aberrant immunophenotypes were consistently present in CD34+ precursors in JMML, while they were virtually absent in controls. Multivariate logistic regression analysis showed that combined assessment of the number of CD34+CD7+ lymphoid precursors and CD34+ aberrant precursors or erythroid precursors had a great potential in discriminating JMMLs versus controls. Importantly our scoring model allowed highly efficient discrimination of truly JMML versus patients with JMML-like diseases. In conclusion, we show for the first time that CD34+ precursors from JMML patients display a unique immunophenotypic profile which might contribute to a fast and accurate diagnosis of JMML worldwide by applying an easy to standardize single eight-color antibody combination.